截至5月23日收盘，创新药概念上涨0.97%，位居概念板块涨幅第7，板块内，116股上涨，海辰药业20% 涨停，先达股份、众生药业、海翔药业等涨停，阳光诺和、舒泰神、贝达药业等涨幅居前，分别上涨 12.55%、11.77%、8.35%。跌幅居前的有亚虹医药、*ST苏吴、亚泰集团等，分别下跌5.86%、4.98%、 4.35%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 可控核聚变 | 2.38 | 兵装重组概念 | -3.52 | | CRO概念 | 1.51 | 中韩自贸区 | -3.07 | | 细胞免疫治疗 | 1.35 | 快手概念 | -2.89 | | 仿制药一致性评价 | 1.31 | 小红书概念 | -2.60 | | 幽门螺杆菌概念 | 1.28 | 财税数字化 | -2.60 | | 减肥药 | 1.27 | 共享单车 | -2.52 | | 创新药 | 0.97 | 云游戏 | -2.52 | | 光刻胶 | 0.94 | 算力租赁 | -2.50 | | 肝炎概念 | 0.89 ...

Core Viewpoint - Binzhou City is committed to implementing the "industrial city, manufacturing strong city" strategy, focusing on transforming traditional industries, promoting emerging industries, and developing a modern industrial system with strong support [1][16]. Group 1: Industrial Development - Binzhou has cultivated five trillion-level pillar industries, four strategic emerging industries, and three future industries, establishing a matrix of industrial development [1][16]. - The city has built two provincial advanced manufacturing clusters and seven provincial characteristic industrial clusters, maintaining its position as one of the top 100 advanced manufacturing cities in the country for four consecutive years [1][16]. - In 2024, the revenue for high-end aluminum, fine chemicals, and intelligent textile industry clusters is projected to reach 471.1 billion yuan, 241.3 billion yuan, and 192 billion yuan respectively, showcasing the strong momentum of industrial transformation [1][16]. Group 2: Economic Performance - Binzhou's GDP is expected to exceed 340 billion yuan in 2024, achieving a year-on-year growth of 6.2%, which is higher than the national average [4]. - The industrial output value above designated size is projected to grow by 9.6% year-on-year, with manufacturing growth at 11.8%, particularly in equipment manufacturing, which is expected to grow by 16.1% [6]. - High-tech manufacturing value added is expected to grow by 22.3%, significantly outpacing the average growth rate of industrial enterprises [6]. Group 3: Innovation and Technology - The number of national high-tech enterprises in Binzhou has surpassed 800, with a year-on-year growth of 21.3%, maintaining over 20% growth for three consecutive years [8]. - The city has approved 66 provincial-level technology projects, receiving 220 million yuan in financial support, marking a historical high [8]. - The establishment of the "Binzhou Aluminum Industry Advanced Manufacturing Provincial Laboratory" represents a significant breakthrough in innovation platform construction [8]. Group 4: Policy Framework - The "New Quality Productive Forces" concept has been incorporated into the national strategy, with Binzhou actively responding by implementing policies to foster innovation and industrial development [10][11]. - A series of forward-looking policies have been introduced to support the development of advanced manufacturing clusters and new generation information technology industries [11][14]. - The government aims to create a manufacturing strong city with core competitiveness by focusing on high-end, intelligent, green, and clustered industrial development [11][16]. Group 5: Future Trends - Binzhou is expected to strengthen traditional industry upgrades, particularly in high-end aluminum, and expand into new areas such as renewable energy and low-altitude economy [27][30]. - The integration of digital technology and intelligent manufacturing is anticipated to enhance industrial transformation, with plans to cultivate over 500 benchmark enterprises [29]. - The city aims to optimize its innovation ecosystem, enhancing collaboration between government, industry, academia, and research to boost technology transfer and innovation [31].

Investment Rating - The report does not explicitly state the investment rating for Shandong Cynda Chemical Core Insights - In Q1 2025, the company achieved a non-recurring net profit of 20 million yuan, a year-on-year increase of 224%. The operating income reached 543 million yuan, up 10.78% year-on-year, with total profit at 24 million yuan, a 296.51% increase. The net profit attributable to the parent company was 22 million yuan, reflecting a 257.63% increase. The growth was driven by increased sales volume and prices of major products [2][3]. - The market for clethodim remains tight, with prices continuing to rise. The mainstream transaction reference price for clethodim was 130,000 yuan per ton, an increase of 10,000 yuan per ton (up 8.33%) from the previous week. Low market inventory and strong demand are contributing to this price increase [4]. - The company has made significant progress in original drug R&D, establishing a product matrix centered on quinclorac, pyrazoxyfen, and Feproxydim. The first product, quinclorac, has been widely applied, while the second product, pyrazoxyfen, is set to launch in 2025. The third product, Feproxydim, is currently under review [5]. Summary by Sections Financial Performance - In Q1 2025, the company reported: - Operating income: 543 million yuan, up 10.78% year-on-year - Total profit: 24 million yuan, up 296.51% year-on-year - Net profit attributable to parent company: 22 million yuan, up 257.63% year-on-year - Non-recurring net profit: 20 million yuan, up 224% year-on-year - Gross profit margin: 17.78%, up 4.97 percentage points year-on-year - Net profit margin: 3.92%, up 6.73 percentage points year-on-year [2][3]. Market Dynamics - The supply-demand situation for clethodim remains tight, with strong demand and low inventory levels. Most enterprises can schedule orders until July. The price of clethodim has increased significantly due to this tight market condition [4]. R&D Developments - The company has established a core matrix of innovative products, with successful registrations and applications of its herbicides. The first product, quinclorac, has been applied in over 2 million mu of fields, while the second product, pyrazoxyfen, is expected to launch in 2025. The third product is under review, and additional herbicides are set to begin registration processes in 2025 [5].

Investment Rating - The report does not explicitly state the investment rating for Shandong Cynda Chemical Core Insights - The company's product volume and price have both increased, with the price of clethodim continuing to rise [1][4] - In Q1 2025, the company achieved a non-recurring net profit of 20 million yuan, a year-on-year increase of 224%, and an operating income of 543 million yuan, a year-on-year increase of 10.78% [2][3] - The gross profit margin was 17.78%, an increase of 4.97 percentage points year-on-year, while the net profit margin was 3.92%, an increase of 6.73 percentage points year-on-year [2][3] Summary by Sections Financial Performance - In Q1 2025, the total profit reached 24 million yuan, a year-on-year increase of 296.51%, and the net profit attributable to the parent company was 22 million yuan, a year-on-year increase of 257.63% [2][3] - The performance growth was driven by increased sales volume and price of major products [2][3] Market Conditions - The supply and demand in the market remain tight, with the mainstream transaction reference price of clethodim at 130,000 yuan per ton, an increase of 10,000 yuan per ton (up 8.33%) from the previous week [4] - Market spot inventory is low, and demand remains strong, with most enterprises able to schedule orders until July [4] Product Development - The company has made significant progress in original drug R&D, establishing a core matrix of innovative products including quinclorac, pyrazoxyfen, and Feproxydim [5] - The first original product, quinclorac, has been applied in over 2 million mu of sorghum fields, with rapidly growing sales [5] - The second original herbicide, pyrazoxyfen, is set to launch in 2025, while the third innovative herbicide, Feproxydim, is currently under review [5]

证券代码：603086 证券简称：先达股份 公告编号：2025-034 山东先达农化股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 1、公司在任董事7人，出席6人，董事王申健因工作原因无法出席本次会议； 2、公司在任监事3人，出席1人，监事李刚先生、王小丽女士因工作原因无 法出席本次会议； 3、公司董事会秘书、财务总监江广同先生出席本次会议，部分高级管理人 员列席本次会议。 (一)股东大会召开的时间：2025 年 5 月 20 日 (二)股东大会召开的地点：济南市高新区新泺大街 2008 号银荷大厦 D 座 6 楼会 议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 197 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 135,855,760 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数 ...

北京 上海 南京 杭州 天津 深圳 高朋（上海）律师事务所 关于山东先达农化股份有限公司 2024 年年度股东大会的 法律意见书 2025 年 5 月 扬州 中国上海市徐汇区虹桥路 500 号中城国际大厦 23 楼 邮编：200030 电话/Tel：（8621）5039-2800 传真/Fax：（8621）5039-2800 网址：http://www.gaopenglaw.com www.gaopenglaw.com 中国·上海·徐汇区虹桥路 500 号 中城国际大厦 23 楼 23/F CURA International Center , No 500 HongQiao Road , XuHui District , Shanghai , 200030 ,China 电话/Tel：（8621）5039-2800 传真/Fax：（8621）5039-2800 www.gaopenglaw.com 高朋（上海）律师事务所 关于山东先达农化股份有限公司 2024 年年度股东大会的 法律意见书 致：山东先达农化股份有限公司 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事 ...

Group 1 - The company held its 2024 annual performance briefing on May 16, 2025, via an online interactive format [1] - Key executives, including the board secretary and CFO, participated in the briefing and addressed investor inquiries [1] - The company emphasized the significant potential of its innovative herbicides in overseas markets, particularly in rice cultivation areas in Latin America and Southeast Asia, where efficacy assessments have been completed [1][2] Group 2 - The company has two innovative herbicides already on the market, with another undergoing registration review, indicating a strong growth trajectory for innovative herbicide revenue in the coming years [1][2] - The company highlighted the broad application potential of its herbicide, Pyrazosulfuron, in rice fields, which are critical for weed management [1] - The company acknowledged the challenges of industry homogenization and stressed the importance of technological innovation and strategic positioning for future growth [1]

证券代码：603086 证券简称：先达股份 公告编号：2025-033 山东先达农化股份有限公司 关于 2024 年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东先达农化股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日（星期五） 13:00-14:00 在上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/）， 以网络文字互动方式召开公司 2024 年度业绩说明会。关于本次业绩说明会的召开事项， 公司已于 2025 年 5 月 9 日在《中国证券报》《上海证券报》《证券时报》《证券日报》 及上海证券交易所网站上披露了《关于召开 2024 年度业绩说明会的公告》（公告编号： 2025-031）。现将有关事项公告如下： 一、本次说明会召开情况 2025 年 5 月 16 日，公司董事长王现全先生、独立董事袁成雷先生、董事兼总经理 门亮先生、董事会秘书兼财务总监江广同先生出席了本次说明会，并对投资者提出的问 题进行了回答。 二、投资者提出 ...

Core Viewpoint - The company is focusing on the development of new drugs and enhancing its product commercialization process to improve profitability and return value to investors [1][4][5] Group 1: Product Development and Market Strategy - The company is actively developing new drugs, including the integration of seed and pesticide solutions, with ongoing research and development efforts [2][4] - The new product, Pyrazol Quinclorac, is currently in the market promotion phase, indicating a strategic push for new product launches [4][5] - The company has completed the domestic market layout for its new products and is entering a phase of increasing sales volume [5][6] Group 2: Production Capacity and Sales - The monthly production capacity for Acetochlor is approximately 1,000 tons, and the company is currently operating at full capacity due to high demand [3][5] - The company is not planning to expand the production capacity for Acetochlor, focusing instead on new drug development [2][4] - The company anticipates significant profit growth in 2025 due to rising prices of Acetochlor and strong market demand [4][5] Group 3: Market Demand and Pricing - The global demand for Acetochlor is estimated at around 35,000 tons, with expectations for varying growth rates annually [3][4] - The company is experiencing a tight supply situation for Acetochlor, particularly during peak sales seasons [4][5] - The pricing of products is influenced by supply and demand dynamics, with recent price increases expected to enhance profitability [5][6]

证券代码： 603086 证券简称：先达股份 山东先达农化股份有限公司投资者关系活动记录表 | 投资者关系活动 | □特定对象调研 分析师会议 □ | | --- | --- | | 类别 □ | 媒体采访 业绩说明会 √ | | □ | 新闻发布会 路演活动 □ | | □ | 现场参观 | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 年山东辖区上市公司投资者网上集体接待日"投资 参与"2025 | | 人员姓名 者 | | | 时间 | 2025 年 5 月 15 日 (周四) 下午 15:00~16:30 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、董事兼总经理门亮 | | 员姓名 | 2、董事会秘书兼财务总监江广同 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： 1、您好，目前公司烯草酮生产成本一吨是多少万，除目前 | | | 已明确产能以外，公司有没有继续扩大产能的计划安排？ | | | 您好，感 ...